Olink

Olink®
Part of Thermo Fisher Scientific

Characterization of Cardiac Sympathetic Nervous System and Inflammatory Activation in HFpEF Patients

JACC: Basic to Translational Science, 2022

Kaye D., Nanayakkara S., Wang B., Shihata W., Marques F., Esler M., Lambert G., Mariani J.

Disease areaApplication areaSample typeProducts
CVD
Pathophysiology
Plasma
Olink Target 96

Olink Target 96

Abstract

We have shown that systemic and cardiac sympathetic activation is present in heart failure with preserved ejection fraction (HFpEF) patients. Conversely, whereas systemic inflammatory activation was also detected in HFpEF, we did not detect local myocardial release of inflammatory cytokines. Activation of the sympathetic system correlated with both hemodynamic and demographic factors that characteristically cluster together in HFpEF. Together these data suggest that there may be a role for antiadrenergic therapies in certain HFpEF patients. The study does not implicate locally derived cytokines in the myocardial biology of HFpEF, although systemic sources may contribute to the global pathophysiology of HFpEF.

Read publication ↗